Advertisement

Mode of Detection of Second Events in Routine Surveillance of Early Stage Breast Cancer Patients

      Abstract

      Introduction

      NCCN and ASCO guidelines recommend breast cancer (BC) follow-up to include clinical breast examination (CBE) every 6 months and annual mammography (AM) for 5 years. Given limited data to support CBE, we evaluated the modes of detection (MOD) of BC-events in a contemporary practice.

      Methods

      We conducted a retrospective review of registry patients with early stage BC (DCIS, Stage I or II) diagnosed between 2010 and 2015 with at least 5 years of follow-up. Second events were defined as malignant (contralateral primary, ipsilateral breast tumor recurrence (IBTR), chest wall recurrence, regional node recurrence or distant relapse) or benign. MOD was categorized as patient complaint, clinical examination or breast imaging.

      Results

      Sixty-three of 351 BC patients experienced second events. 15 had BC malignant events, including 4 distant disease, 5 contralateral primary, and 3 IBTR. 7/8 of IBTR and contralateral primary BC were AM detected. Patient complaints identified 4/4 distant relapses. Clinical exam identified 2/2 chest wall recurrences in post-mastectomy patients.

      Conclusions

      Only 2.8% (10/351) of early stage BC patients experienced recurrence during 5 years of follow-up. AM was the predominate MOD of both IBTR and new contralateral primary following breast conserving therapy. Patient complaints prompted evaluation for distant disease. Provider CBE was MOD in only 2/351, 0.6% 95% CI (2.1%-0.1%) of patients as chest wall recurrences postmastectomy. Given modern enhancements to imaging and lower recurrence rates, this data encourages the reassessment of guidelines for every 6-month CBE and provides basis to study telehealth in survivorship care.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • DeSantis C.E.
        • Ma J.
        • Gaudet M.M.
        • et al.
        Breast cancer statistics, 2019.
        CA: A Cancer Journal for Clinicians. 2019; 69: 438-451
        • Schumacher J.R.
        • Neuman H.B.
        • Zhang Y.
        • et al.
        Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study.
        Journal of Clinical Oncology. 2017; 35 (-6520): 6520
        • Schneble E.J.
        • Graham L.J.
        • Shupe M.P.
        • et al.
        Current approaches and challenges in early detection of breast cancer recurrence.
        J Cancer. 2014; 5: 281-290
        • Montgomery D.A.
        • Krupa K.
        • Cooke T.G.
        Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature.
        Br J Cancer. 2007; 97: 1632-1641
        • Runowicz C.D.
        • Leach C.R.
        • Henry N.L.
        • et al.
        American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
        Journal of Clinical Oncology. 2016; 34: 611-635
        • Moran W.G.M.
        Breast Cancer Version 4.2021.
        NCCN Clinical Practice Guidelines in Oncology. April 28, 2021; : ed2021
        • Zon R.T.
        • Kennedy E.B.
        • Adelson K.
        • et al.
        Telehealth in Oncology: ASCO Standards and Practice Recommendations.
        JCO Oncology Practice. 2021; 17: 546-564
        • McGrowder D.A.
        • Miller F.G.
        • Vaz K.
        • et al.
        The Utilization and Benefits of Telehealth Services by Health Care Professionals Managing Breast Cancer Patients during the COVID-19 Pandemic.
        Healthcare. 2021; 9: 1401
        • Collins L.C.
        • Achacoso N.
        • Haque R.
        • et al.
        Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.
        Breast cancer research and treatment. 2013; 139: 453-460
        • Voogd A.C.
        • Nielsen M.
        • Peterse J.L.
        • et al.
        Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.
        Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001; 19: 1688-1697
        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • Jemal A.
        Cancer Statistics, 2021.
        CA: A Cancer Journal for Clinicians. 2021; 71: 7-33
      1. Cancer.Net. Breast Cancer: Statistics. 2021; ([cited 2021 12/21/2021]; Available from:)
        • Cox A.
        • Lucas G.
        • Marcu A.
        • et al.
        Cancer Survivors’ Experience With Telehealth: A Systematic Review and Thematic Synthesis.
        J Med Internet Res. 2017; 19: e11
        • Larson J.L.
        • Rosen A.B.
        • Wilson F.A.
        The effect of telehealth interventions on quality of life of cancer survivors: A systematic review and meta-analysis.
        Health Informatics Journal. 2020; 26: 1060-1078
        • Li J.
        • Liu Y.
        • Jiang J.
        • Peng X.
        • Hu X.
        Effect of telehealth interventions on quality of life in cancer survivors: A systematic review and meta-analysis of randomized controlled trials.
        International Journal of Nursing Studies. 2021; 122103970
        • Lehman C.D.
        • Arao R.F.
        • Sprague B.L.
        • et al.
        National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium.
        Radiology. 2017; 283: 49-58